AGENT FOR FUNGAL DERMATITIS

(19)

(11)

EP 2 191 825 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.09.2016 Bulletin 2016/38

(45)	Mention of the grant of the patent:
	25.05.2016 Bulletin 2016/21

(21)	Application number: 08792732.3

(22)	Date of filing: 26.08.2008

(51)

International Patent Classification (IPC):

A61K 31/4178^(2006.01)
A61K 47/14^(2006.01)
A61K 47/36^(2006.01)
A61P 31/10^(2006.01)

A61K 47/10^(2006.01)
A61K 47/34^(2006.01)
A61P 17/08^(2006.01)
C07D 409/06^(2006.01)

(86)	International application number:
	PCT/JP2008/065186

(87)	International publication number:
	WO 2009/028495 (05.03.2009 Gazette 2009/10)

(54)	AGENT FOR FUNGAL DERMATITIS MITTEL GEGEN PILZDERMATITIS AGENT POUR UNE DERMATITE FONGIQUE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

27.08.2007 JP 2007219333
09.11.2007 JP 2007292284

(43)	Date of publication of application:
	02.06.2010 Bulletin 2010/22

(73)	Proprietor: NIHON NOHYAKU CO., LTD.
	Tokyo 103-8236 (JP)

(72)	Inventors:
	KOGA, Hiroyasu Kawachinagano-shi Osaka 586-0094 (JP) NANJOH, Yasuko Kawachinagano-shi Osaka 586-0094 (JP) KANEDA, Hideo Kawachinagano-shi Osaka 586-0094 (JP)

(74)	Representative: Duckworth, Timothy John
	J A Kemp 14 South Square Gray's Inn London WC1R 5JJ London WC1R 5JJ (GB)

(56)

References cited: :

WO-A1-98/43673
WO-A1-2005/032530

WO-A1-98/52518

UCHIDA KATSUHISA ET AL: "In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species." INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 21, no. 3, March 2003 (2003-03), pages 234-238, XP009136976 ISSN: 0924-8579
HIROYASU KOGA ET AL: "In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses" JOURNAL OF INFECTION AND CHEMOTHERAPY ; OFFICIAL JOURNAL OF THE JAPANESE SOCIETY OF CHEMOTHERAPY AND THE JAPANESE ASSOCIATION FORINFECTIOUS DISEASES, SPRINGER-VERLAG, TO LNKD- DOI:10.1007/S10156-006-0440-4, vol. 12, no. 3, 1 June 2006 (2006-06-01), pages 163-165, XP019387280 ISSN: 1437-7780
NIWANO YOSHIMI ET AL: "In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 42, no. 4, 1 April 1998 (1998-04-01), pages 967-970, XP002315888 ISSN: 0066-4804
WATANABE S ET AL: "A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. (vol 49, pg 236, 2006)" MYCOSES, vol. 49, no. 5, September 2006 (2006-09), page 441, XP009137837 ISSN: 0933-7407
FOLIA PHARMACOLOGICA JAPONICA vol. 127, no. 5, pages 408 - 414, XP008131228
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS vol. 21, no. 3, pages 234 - 238, XP008131229
JPN. J. MED. MYCOL. vol. 33, pages 217 - 220, XP008131231
BASIC PHARMACOLOGY & THERAPEUTICS vol. 8, no. 2, pages 153 - 170


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).